Spero Therapeutics Inc
SPRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$163.86M
Close$
$5.29
89.1% upside
Current Fair Value
89.1% upsideUndervalued by 89.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $163.86 Million |
|---|---|
| Enterprise Value | $110.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 1.43 |
| Outstanding Shares | 57,281,570 |
Return
| Return on Equity | 28.78% |
|---|---|
| Return on Assets | 25.81% |
| Return on Invested Capital | 22.32% |
Valuation & Multiples
| P/E Ratio | 10.64 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.93 |
| Enterprise Value to EBIT | 9.24 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$3.34 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$281,947
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6977▲ 169.77% |
|---|---|
| Total Calls | 64,500▲ Infinity% |
| Total Puts | 109,500▼ 1.97% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.85%▼ 0.68% |
|---|---|
| Total Invested | $48.30M▼ 1.86% |
| Investors Holding | 55▼ 3.00% |
ESG Score
No data
About Spero Therapeutics Inc
89 employees
CEO: Ankit Mahadevia Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.